Phase IB/II Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 27 Apr 2017
At a glance
- Drugs Tocilizumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Apr 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 02 Mar 2017 Planned primary completion date changed from 1 Jul 2022 to 1 Jul 2020.
- 22 Dec 2016 New trial record